SCHEMBL269119

SCHEMBL269119

CCN(CC)Cc1cccc(C(=O)Nc2ccc(Cl)cc2C(=O)OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.55
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
HPGD P15428 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
ACHE P22303 1/20 0.53
AKR1C4 P17516 1/20 0.50
AKR1C3 P42330 1/20 0.50
AKR1C2 P52895 1/20 0.50
AKR1C1 Q04828 1/20 0.50
SERPINE1 P05121 2/20 0.48
MAPT P10636 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
POLB P06746 2/20 0.45
GAA P10253 1/20 0.45
GFER P55789 1/20 0.45
BCHE P06276 1/20 0.45
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268502 0.89 AKR1C4 (0.65) F10ALDH1A1KDM4EACHEAKR1C4
SCHEMBL267931 0.86 HPGD (0.57) ALDH1A1KDM4ESMN1; SMN2HPGDNPC1
SCHEMBL268333 0.86 ACHE (0.52) F10ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL274496 0.85 NPC1 (0.54) F10ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL418984 0.82 GRIK1 (0.64) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL3050158 0.81 POLB (0.56) ALDH1A1KDM4ESMN1; SMN2HPGDNPC1
SCHEMBL418492 0.80 AKR1C4 (0.57) ALDH1A1KDM4ESMN1; SMN2HPGDNPC1
SCHEMBL420185 0.78 SERPINE1 (0.77) ALDH1A1KDM4ESMN1; SMN2HPGDNPC1
SCHEMBL265420 0.78 KDM4E (0.46) ALDH1A1KDM4ESMN1; SMN2HPGDNPC1
SCHEMBL266797 0.77 HPGD (0.48) ALDH1A1KDM4ESMN1; SMN2HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 F10 188/4885ALDH1A1 3022/4885KDM4E 4468/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 F10 338/4885ALDH1A1 2872/4885KDM4E 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.